CEPI Commits $30M to Boost Zaire Ebolavirus Vaccine Accessibility
Event summary
- CEPI to provide up to $30M to MSD for Zaire ebolavirus vaccine development, with SK bioscience and Hilleman Laboratories as key partners.
- Collaboration aims to improve manufacturing yield and thermostability to address cold-chain challenges in low-resource settings.
- SK bioscience and IDT Biologika will lead manufacturing process improvements, while Hilleman Laboratories oversees clinical development.
- Project builds on MSD's existing WHO-prequalified Zaire ebolavirus vaccine, targeting more affordable and sustainable supply.
- Funding follows recent Ebola outbreaks in the Democratic Republic of the Congo, highlighting ongoing global health risks.
The big picture
This collaboration addresses critical logistical challenges in Ebola vaccine distribution, particularly in regions with limited healthcare infrastructure. The $30M CEPI funding underscores the urgency of improving vaccine accessibility amid recurring outbreaks. The partnership leverages SK bioscience's manufacturing expertise and MSD's existing WHO-prequalified vaccine to enhance global health preparedness.
What we're watching
- Manufacturing Innovation
- Whether SK bioscience and IDT Biologika can successfully enhance vaccine thermostability to reduce cold-chain dependencies.
- Regulatory Approval
- The pace at which the updated vaccine secures regulatory approvals for deployment in low-resource settings.
- Market Access
- How the collaboration will impact vaccine affordability and long-term sustainability in low- and middle-income countries.
Related topics